CHARLOTTETOWN, PRINCE EDWARD ISLAND--(Marketwire - June 24, 2011) -SOLARVEST BIOENERGY INC. (TSX VENTURE:SVS) ("Solarvest" or the "Company") is pleased to announce that it has granted to Dr. Angela Riveroll 70,000 options exercisable at a price of $0.25 per common share for a period of five years from the grant date. As Senior Research Scientist at Solarvest (PEI) Inc., Dr. Riveroll will take a leading role in the company's genetic program to produce hydrogen from its proprietary strains of algae.
About Solarvest: Solarvest is committed to the development of sustainable and renewable energy sources to meet growing energy demands and environmental challenges. Solarvest's intellectual property is a biologically-based hydrogen producing technology, which provides a method for controlling key genes in algae resulting in the continuous production of hydrogen gas. Solarvest's bio-energy production system utilizes light and carbon dioxide to produce hydrogen leaving a clean positive environmental footprint.
The statements made in this news release may contain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results could differ materially from the Company's expectations and projections.
The TSX Venture Exchange has neither approved nor disapproved the contents of this news release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information:
Gerri Greenham
Chief Executive Officer
416 420 0947
ggreenham@solarvest.ca